(NASDAQ: JANX) Janux Therapeutics's forecast annual revenue growth rate of 14.35% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.67%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.8%.
Janux Therapeutics's revenue in 2025 is $9,336,000.On average, 4 Wall Street analysts forecast JANX's revenue for 2025 to be $480,798,151, with the lowest JANX revenue forecast at $147,937,893, and the highest JANX revenue forecast at $591,751,570. On average, 2 Wall Street analysts forecast JANX's revenue for 2026 to be $369,844,731, with the lowest JANX revenue forecast at $295,875,785, and the highest JANX revenue forecast at $443,813,678.
In 2027, JANX is forecast to generate $910,113,915 in revenue, with the lowest revenue forecast at $147,937,893 and the highest revenue forecast at $1,990,652,281.